Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Călugăru D, Călugăru M . Comment on: ‘Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab’. Eye 2016; 30: 766.
Papakostas TD, Lim L, van Zyl T, Miller JB, Modjtahedi BS, Andreoli CM et al. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. Eye 2016; 30: 79–84.
Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG . Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology 2013; 120: 1057–1063.
Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124–1133.e1.
Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 2013; 156: 29–35.e2.
Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013; 156: 15–22.e1.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Papakostas, T., Vavvas, D., Eliott, D. et al. Reply to ‘Comment on: Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizmab’. Eye 30, 766–767 (2016). https://doi.org/10.1038/eye.2016.6
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2016.6
